Previous 10 | Next 10 |
home / stock / bcli / bcli articles
NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential se...
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group ...
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 100 points on Thursday. The Dow traded up 0.40% to 33,683.43 w...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining 1% on Thursday. The Dow traded up 0.58% to 33,745.23 while the ...
U.S. stocks traded higher this morning, with the Dow Jones gaining around 80 points on Thursday. Following the market opening Thursday, the Dow tra...
The FDA's Cellular, Tissue and Gene Therapies Advisory Committee meeting reviewing BrainStorm Cell Therapeutics Inc's (NASDAQ: BC...
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares rose 69.9% to $0.7391 in pre-market trading. The company announced the effective date for its revers...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher by around 30 points on Monday. The Dow traded down 0.0...
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with ...
News, Short Squeeze, Breakout and More Instantly...
Brainstorm Cell Therapeutics Inc. Company Name:
BCLI Stock Symbol:
NASDAQ Market:
Brainstorm Cell Therapeutics Inc. Website:
BCLI Update - Progress Supports Our 10x Plus Value Range Potential Canada NewsWire ACF Equity Research FROM ACF EQUITY RESEARCH HEALTHCARE TEAM LONDON , July 24, 2024 /CNW/ -- NASDAQ: BCLI READ ACF EQUITY RESEARCH'S UPDATE NOTE HERE READ...
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program PR Newswire A conference call and webcast will be held Monday, July 8 , at 8:00 a.m. Eastern Time NEW YORK , July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeut...
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering PR Newswire NEW YORK , June 27, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics fo...